Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pitavastatin calcium + choline fenofibrate
- Development stage
- Unknown
- Lead developer
- Daewon Pharm
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Pitapenocol SR is a fixed-dose combination sustained-release tablet developed by Myungmoon Pharm for the treatment of mixed dyslipidemia. It combines pitavastatin calcium (2 mg), an HMG-CoA reductase inhibitor (statin) that effectively lowers low-density lipoprotein cholesterol (LDL-C), with choline fenofibrate (equivalent to 135 mg of fenofibric acid), a peroxisome proliferator-activated receptor alpha (PPAR-alpha) agonist that reduces triglycerides (TG) and increases high-density lipoprotein cholesterol (HDL-C). By incorporating a choline salt, the formulation enhances the solubility and absorption of fenofibrate, allowing for consistent therapeutic efficacy regardless of food intake. Pitapenocol SR was approved and launched in South Korea in May 2026.
- Brand names
- Pitacholine SRPitapenocol SRTabapheno SRUptava SR
- Other names
- pitavastatin + choline fenofibratepitavastatin + fenofibrate cholinepitavastatin + fenofibric acidpitavastatin calcium + fenofibrate cholinepitavastatin calcium + fenofibric acid업타바서방정타바페노서방정피타콜린서방정피타페노콜서방정
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)APOA5 (Apolipoprotein A-V)APOC3 (Apolipoprotein C-III)LPL (Lipoprotein lipase)PPARA (Peroxisome proliferator-activated receptor alpha)RXRA (Retinoid X receptor alpha)
Beyond the preview
Go deeper on pitavastatin calcium + choline fenofibrate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pitavastatin calcium + choline fenofibrate.